Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
复制标题
病例报告：卡瑞利珠单抗和阿帕替尼联合治疗对高钙血症型卵巢小细胞癌的重度治疗产生持久反应
DOI：
10.3389/fonc.2022.916790
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Jiang, Yao
中科院分区：
文献类型：
--
作者：
Li, Guiling;Jiang, Yao
关键词：
卵巢高钙型小细胞癌(SCCOHT)是一种罕见且高度侵袭性的恶性肿瘤，预后不良。大多数患者即使在手术和化疗后也会复发，而且对于复发的疾病没有标准的治疗方案。在此，我们报告一位患有SCCOHT的36岁女性患者，她在没有辅助性化疗的情况下接受了一次细胞减少术，并保持了9个月的无病状态。随后，她出现腹膜后淋巴结转移，并接受了博莱霉素/依托泊苷/顺铂两个周期的化疗。然而，病情恶化，患者接受了四个周期的脂质体阿霉素/异环磷酰胺化疗，然后局部放射到扩大的腹膜后淋巴结。她获得了13个月的部分缓解，之后病情再次恶化。肿瘤组织和血液样本被送往下一代测序。结果表明，该基因是一种与SWI/SNF相关、基质相关、肌动蛋白依赖的染色质调节因子，亚家族A，成员4(SMARCA4)突变，微卫星稳定性，肿瘤突变负荷为1.0muts/Mb，没有任何胚系突变。患者接受了抗PD-1抗体Camrelizumab和抗血管生成药物Apatinib的治疗，并获得了28个月的部分缓解。我们的研究首次提供了临床证据，证明卡米珠单抗和阿帕替尼联合治疗复发性SCCOHT是一种有效的治疗方法。
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and highly aggressive malignancy with a poor prognosis. Most patients experience recurrence even after surgery and chemotherapy, and there are no standard treatment options for recurrent disease. Here, we report the case of a 36-year-old woman with SCCOHT who underwent primary cytoreductive surgery without adjuvant chemotherapy and remained disease-free for 9 months. She then developed retroperitoneal lymph node metastasis and was treated with two cycles of bleomycin/etoposide/cisplatin chemotherapy. However, the disease progressed and the patient received four cycles of liposomal doxorubicin/ifosfamide chemotherapy, followed by local radiation to the enlarged retroperitoneal lymph nodes. She achieved partial remission for 13 months, after which the disease progressed again. Tumor tissues and blood samples were sent for next-generation sequencing. The results indicated a somatic SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4) mutation, microsatellite stability, and a tumor mutation burden of 1.0 muts/Mb without any germline mutations. An anti-PD-1 antibody, camrelizumab, and an antiangiogenic agent, apatinib, were administered, and the patient achieved partial remission for 28 months. Our study provides the first clinical evidence that the combination therapy of camrelizumab and apatinib could be an effective treatment for recurrent SCCOHT.
登录
查看更多内容
DOI：
10.1093/jnci/djx277
发表时间：
2018-07-01
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Jelinic P;Ricca J;Van Oudenhove E;Olvera N;Merghoub T;Levine DA;Zamarin D
通讯作者：
Zamarin D
影响因子：
1.9
作者：
Ratnayake, Gishan;Shanker, Mihir;Chua, Benjamin
通讯作者：
Chua, Benjamin
DOI：
10.1111/igc.0b013e3181a1a116
发表时间：
2009-04-01
影响因子：
4.8
作者：
Dykgraaf, Ramon H. M.;de Jong, Diederick;van der Burg, Maria E. L.
通讯作者：
van der Burg, Maria E. L.
影响因子：
4.7
作者：
Callegaro-Filho D;Gershenson DM;Nick AM;Munsell MF;Ramirez PT;Eifel PJ;Euscher ED;Marques RM;Nicolau SM;Schmeler KM
通讯作者：
Schmeler KM
影响因子：
50.5
作者：
Pautier, P.;Ribrag, V.;Lhomme, C.
通讯作者：
Lhomme, C.